Australian Man Survives 100 Days On Titanium Artificial Heart

In Australia, a man was kept alive for 100 days on an artificial heart made of titanium while a donor heart was eventually found.

This is the longest-ever period that a man has been kept alive by an artificial heart, giving its developers encouragement that it can play a major role in supporting waiting list patients whose hearts are failing.

5 months ago, a man in his forties received the BiVACOR Total Artificial Heart (TAH) after experiencing heart failure. The TAH has no pumps, valves, or other moving parts susceptible to wear. Instead, magnetic levitation permits a single rotor to pump blood to the body through both ventricles.

He was able to leave the hospital even, before a donor heart was found that was transplanted successfully.

In a statement, BiVACOR, St. Vincent’s Hospital where the surgery was carried out, and Monash University which provided the grant funding for the development of the TAH, said that the result is a sign the artificial heart could potentially offer a long-term option for people suffering from heart failure.

BiVACOR’s founder, Australian bioengineer Daniel Timms, who invented the device, said it was “exhilarating to see decades of work come to fruition.”

“The entire BiVACOR team is deeply grateful to the patient and his family for placing their trust in our Total Artificial Heart,” he said in the statement. “Their bravery will pave the way for countless more patients to receive this lifesaving technology.”

In the United States, there are around 3,500 donor hearts made available every year for more than 4,400 people who join the waiting list.

The TAH has already been tested in an early feasibility study in search of eventual FDA approval. 5 patients received the device, CNN reports, with the first being last July, when a 58-year-old man suffering end-stage heart failure received the implant during surgery at Texas Medical Center.

The four others also received it successfully, and organizers hope to expand it to 15 patients.

Australian Man Survives 100 Days on Titanium Artificial Heart

In a groundbreaking medical milestone, an Australian man in his forties lived for over 100 days using an artificial heart made entirely of titanium, setting a new record for the longest period a person has survived with such a device. The breakthrough not only saved his life while he awaited a donor heart, but also marked a major step forward for the future of artificial organ technology.

Revolutionary Technology Offers Hope to Heart Failure Patients

Five months ago, the patient suffered from advanced heart failure—a condition in which the heart becomes too weak to pump blood effectively to the rest of the body. With no donor heart immediately available, doctors opted to implant the BiVACOR Total Artificial Heart (TAH), a state-of-the-art device unlike anything previously used in cardiac care.

The BiVACOR TAH is engineered with innovation at its core. Unlike traditional artificial hearts that rely on mechanical pumps or valves—components that are prone to wear and tear over time—this artificial heart uses magnetic levitation technology. A single rotor, suspended in a magnetic field, efficiently pumps blood through both ventricles of the body without any moving parts in direct contact. This design significantly reduces the risk of mechanical failure, offering a more durable and potentially longer-lasting solution for patients.

Leaving the Hospital Before a Transplant

What made the case even more remarkable was the patient’s condition following surgery. Not only did he survive with the device, but he also regained enough strength and stability to leave the hospital before receiving a donor heart. Eventually, a suitable donor was found, and the transplant was carried out successfully.

In a joint statement, BiVACOR, St. Vincent’s Hospital—where the procedure was performed—and Monash University, which provided research funding, celebrated the achievement. They emphasized that the successful use of the artificial heart suggests it could one day serve as a long-term solution for people living with end-stage heart failure.

Inventor Celebrates a Lifelong Dream Realized

BiVACOR was founded by Australian biomedical engineer Daniel Timms, who dedicated decades to developing the artificial heart. The recent success represents the culmination of years of research, testing, and clinical development.

“It was exhilarating to see decades of work come to fruition,” said Timms. Expressing appreciation to the patient and his loved ones, he added, “The entire BiVACOR team is deeply grateful to the patient and his family for placing their trust in our Total Artificial Heart. Their bravery will pave the way for countless more patients to receive this lifesaving technology.”

Addressing the Global Organ Shortage

Globally, heart failure continues to claim millions of lives each year. In the United States alone, more than 4,400 people are added to the heart transplant waiting list annually, yet only around 3,500 donor hearts become available. The gap between supply and demand highlights the urgent need for alternatives such as artificial hearts.

The BiVACOR TAH could be a game-changer in this area. By providing patients with a durable, stable interim solution, or potentially even a permanent one, artificial hearts may one day ease the pressure on transplant lists and improve survival rates for heart failure patients.

Progress Toward FDA Approval in the United States

The success in Australia is not an isolated case. The BiVACOR artificial heart is already undergoing clinical evaluation in the United States as part of an early feasibility study aimed at obtaining FDA approval. According to CNN, five patients have received the device so far. The first procedure took place in July of last year, when a 58-year-old man with end-stage heart failure was implanted with the artificial heart during surgery at the Texas Medical Center.

All five surgeries were reported as successful, and researchers plan to expand the study to include 15 patients. If the trial continues to produce promising results, the BiVACOR TAH could soon become a widely accepted option in cardiac medicine, potentially saving thousands of lives worldwide.